NCT06947694 A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
| NCT ID | NCT06947694 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Xinqiao Hospital of Chongqing |
| Condition | NSCLC Stage IV Without EGFR/ALK Mutation |
| Study Type | INTERVENTIONAL |
| Enrollment | 427 participants |
| Start Date | 2025-07-02 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 427 participants in total. It began in 2025-07-02 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect. The main objective is to find the optimal organ combination and the best radioimmunotherapy combination pattern.
Eligibility Criteria
Inclusion Criteria: * Patient must meet all of the following inclusion criteria to be enrolled in this study: 1. Non-small cell lung cancer diagnosed initially through pathological histology. 2. There are 3-6 metastatic lesions. 3. No brain metastasis or the lesions are stable. 4. Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET genes. Note: The above English terms are all gene names). 5. ECOG (Eastern Cooperative Oncology Group) score: 0-1 point, with an expected, survival period of more than 3 months. 6. Aged between 18 and 75 years old. 7. Evaluated by PET-CT (including FDG and FMISO, not mandatory). 8. No contraindications for immunotherapy and radiotherapy. 9. The informed consent form has been signed. Exclusion Criteria: * Patients with any of the following criteria are not eligible for enrollment in this study: 1. Those with severe dysfunction of vital organs (heart, liver, kidney). 2. Those accompanied by other malignant tumors. 3. Those with uncontrolled heart diseases or having experienced a myocardial infarction within the past six months. 4. Those with a history of mental illness. 5. And other situations in which the researchers deem it inappropriate for the subjects to participate in the study.
Contact & Investigator
Jianguo Sun, MD
PRINCIPAL INVESTIGATOR
the second affiliated hospital of Army medical university, Chongqing, Chongqing 40037 Recruiting
Frequently Asked Questions
Who can join the NCT06947694 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying NSCLC Stage IV Without EGFR/ALK Mutation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06947694 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06947694 currently recruiting?
Yes, NCT06947694 is actively recruiting participants. Contact the research team at sunjg09@aliyun.com for enrollment information.
Where is the NCT06947694 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06947694 clinical trial?
NCT06947694 is sponsored by Xinqiao Hospital of Chongqing. The principal investigator is Jianguo Sun, MD at the second affiliated hospital of Army medical university, Chongqing, Chongqing 40037 Recruiting. The trial plans to enroll 427 participants.